A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.

Slides:

Advertisements

Similar presentations

TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.

Advertisements

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.

A comparative study of survival models for breast cancer prognostication based on microarray data: a single gene beat them all? B. Haibe-Kains, C. Desmedt,

Introduction MarkerPolymorphisms in CYP2C19 (*2 and *17) assessed by Taqman allelic discrimination ObjectivesTo evaluate the predictive capacity of CYP2C19.

Can we use multigene-tests to guide the adjuvant treatment of early breast cancer? R5 陳三奇 VS 趙大中 J Natl Compr Canc Netw 2013;11: J.

Wildiers H, et al. Lancet Oncol. 2007;8:1101. Breast Cancer in Elderly (>65 Years) Recommendations of the International Society of Geriatric Oncology Surgical.

A 14-gene prognosis signature predicts metastasis risk in node-negative, estrogen receptor-positive, Tamoxifen-treated breast cancer in different ethnogeographic.

Chapter 7 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.

Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.

ER and PR Test Estrogen and Progesterone receptor status tests will show whether or not one or both of these hormones fuel the tumor Cancer that is hormone-sensitive.

Supplemental Figures Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cristina Cadenas 1*, Leonie van de Sandt.

Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.

Breast Cancer Risk with Menopausal Hormone Use Jackie Bouillon Advisor: Dr. Robert Hadley Spring 2007.

Dubsky P et al. Proc SABCS 2012;Abstract S4-3.

TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

Start or Switch?: Latest data from ABCSG/ARNO

Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.

Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer Mayer EL et al. Proc SABCS 2010;Abstract P

Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

A comparative study of survival models for breast cancer prognostication based on microarray data: a single gene beat them all? B. Haibe-Kains, C. Desmedt,

Supplementary Figure 1 Supplementary Figure 1. Kaplan–Meier estimates of recurrence-free survival (RFS) according to the expression of every ten mRNA/lncRNA.

Ab hg fe d c Supplementary Figure 1 Supplementary figure 1: Validation of the ERRα antibody used for immunohistochemical analysis. Control MCF7 breast.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Gene Expression Signatures, Clinicopathological Features,

Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Molecular subclasses of breast cancer: how do we deﬁne them? The IMPAKT 2012 Working Group Statement R4 신재령 / Prof. 김시영 Annals of Oncology 23: 2997–3006,

ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.

Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.

Case 6 A 49 year old female was found to have a 1.3 cm spiculated mass on screening mammogram Ultrasound revealed a 1.2 cm hypoechoic mass with posterior.

Estrogen-Regulated Genes Predict Survival in Hormone Receptor–Positive Breast Cancers J Clin Oncol 24: Daniel S. Oh, Melissa A. Troester,

Prognostic impact of Ki-67 in Croatian women with early breast cancer (single-institution prospective observational study) Ivan Bilić, Natalija Dedić Plavetić,

Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.

Training Set Clinicopathological parameters of the training set

Figure 1. Correlation between estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression in primary breast tumors and synchronous axillary.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716

Picture 3. Higher grade tumors are more frequently Ki67 positive

Figure 2. A consort diagram showing the flowchart of the trial

Hallett, et al., - Supplementary Figure 1

Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors Anita Muthukaruppan, Annette Lasham,

High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.

Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.

A B C Supplementary figure S7

A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer Gen Wang, Xiaosong.

The immune metagene model has prognostic value in IBE but not in IBD breast cancer. The immune metagene model has prognostic value in IBE but not in IBD.

Effect of Obesity on Prognosis after Early Breast Cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer Meng Zhou, Long Hu, Zicheng.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

Down-regulation of LATS1 promotes the formation of tumors enriched in basal-like features. Down-regulation of LATS1 promotes the formation of tumors enriched.

Supplementary Fig S1, Zembutsu H et al.

20-Year Risks of Breast-Cancer Recurrence

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB.

Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.

MW (kDa) 2 µg 0.5 µg Supplementary Figure S1. SDS-PAGE under reducing condition analysis (Coomassie brilliant blue staining) of.

Nadia Howlader, PhD National Cancer Institute

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

Landscape of the TME in gastric cancer and characteristics of TME subtypes. Landscape of the TME in gastric cancer and characteristics of TME subtypes.

Tamoxifen-treated patients.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

MYC and LYN are coexpressed and have interdependent clinical outcomes.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Presentation transcript:

A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates of Distant Event-Free Survival (DEFS) during the first 5 years (left side of each panel) and from 5 to 10 years (right side of each panel) are shown in patients untreated with adjuvant therapy for histological tumor grade (A), Genomic Grade Index (GGI) (B), and PAM50 molecular subtypes (C)

A B Supplementary Figure S2. Hazards rates for recurrences by biomarker groups in untreated and tamoxifen-treated patients Annual hazard rates for distant recurrences by biomarker groups estimates using kernel-based methods for tamoxifen- treated (A) and untreated (B) breast cancers

Supplementary Figure S3. Time-dependent effect of ERS by tertiles in high-MKS tumors (tamoxifen-treated patients) Landmark analyses of the Kaplan-Meier estimates of Distant Event-Free Survival (DEFS) during the first 5 years (left side of each panel) and from 5 to 10 years (right side of each panel) are shown according to tertiles of ERS in highly proliferative (high-MKS) tumors treated with tamoxifen

A B C D Supplementary Figure S4. Prognostic value of biomarkers for early relapse in untreated and tamoxifen-treated patients Kaplan-Maier estimates of Distant Event-Free Survival from 0 to 2.5 years in tamoxifen-treated and untreated patients. Comparisons between high-MKS/low-ERS and all other groups (low-MKS/high-ERS; low-MKS/low-ERS; high-MKS/high- ERS) are presented for untreated (A), tamoxifen-treated (B) and node negative (C) and positive (D) tamoxifen-treated patients. In tamoxifen-treated patients, the prognostic value of nodal status is assessed in groups at low risk for early relapse (E) and the high-MKS/low-ERS group (F) EF

A B C D Supplementary Figure S5. Baseline expression of ERS for tumor relapsing in different time cohorts Box-plot describing the initial ERS value (at diagnosis) for tumor relapsing at different time interval in tamoxifen-treated low- MKS (A) and high-MKS (B) tumors, and in untreated low-MKS (C) and high-MKS (D) tumors. A comparison was performed by Wilcoxon rank-sum test between ERS values in different time cohorts

A B C Supplementary Figure S6. Assessment of the time-dependent prognostic value of MKS, GGI and ER-related luminal genes Landmark analyses of the Kaplan-Meier estimates of Distant Event-Free Survival (DEFS) during the first 5 years (left side of each panel) and from 5 to 10 years (right side of each panel) are shown in tamoxifen-treated patients according to four biomarkers group by combining GGI (low and high) and ERS (high and low) (A), MKS (low and high) and Lum (high and low) (B), GGI (low and high) and Lum (high and low) (C)

A C B Supplementary Figure S7. Correlation between ESR1, ERS and luminal ER-related genes Correlation between ESR1, ERS and the luminal gene based estrogen score are shown. For each paired comparison, the correlation coefficient was calculated using the spearman’s rank test and points were colored according to MKS groups

A B Supplementary Figure S8. Prognostic value of biomarkers for early relapse in tamoxifen-treated pts (cohort 2) Kaplan-Maier estimates of Distant Event-Free Survival from 0 to 2.5 years. Comparisons between high-MKS/low-ERS and all other groups (low-MKS/high-ERS; low-MKS/low-ERS; high-MKS/high-ERS) are presented for node negative (A) and positive (B) patients. the prognostic value of nodal status is assessed in groups at low risk for early relapse (C) and the high-MKS/low-ERS group (E) C D